. Author manuscript; available in PMC: 2014 Jul 28.

Published in final edited form as: Am Heart J. 2012 Feb;163(2):260–7.e3. doi: 10.1016/j.ahj.2011.11.014

Table II.

Patient characteristics

Study Acronym	Mean or median age (years)	Male	Non-ischemic heart failure	Diabetes	Mean or median Baseline EF	Conduction anomaly		Mean or median QRS duration at baseline (milliseconds)	Treatment at baseline			ICD therapy during trials
Study Acronym	Mean or median age (years)	Male	Non-ischemic heart failure	Diabetes	Mean or median Baseline EF	LBBB	RBBB	Mean or median QRS duration at baseline (milliseconds)	ACE inhibitor or angiotensin receptor blocker	Beta-Blocker	Spironolactone	CRT arm	Control arm
COMPANION¹⁰	67	67%	45%	42%	22%	69%	11%	160	89%	67%	54%	0%	0%
CARE-HF^11,15	67	73%	62%	NA	25%	90%	5%	160	95%	72%	56%	2%	5.7%
MADIT-CRT^12,13	65	75%	45%	30%	24%	71%	13%	158	96%	93%	32%	99%	97.4%
RAFT¹⁴	66	83%	33%	34%	23%	72%	9%	157	97%	90%	42%	99%	99%